AVR – anteris technologies global corp. (US:NASDAQ)

News

Anteris Technologies Global (NASDAQ:AVR) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves
Anteris Announces Results for the Third Quarter of 2025
FDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
Anteris Technologies Global (NASDAQ:AVR) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com